Nefritis lúpica Experiencia con dosis reducidas de glucocorticoides en una unidad de enfermedades autoinmunes sistémicas

Abstract

Introduction: current recommendations to treat lupus nephritis (LN) point to low-dose glucocorticoids to control the disease and avoid cumulativedamage. Objective: to learn about and compare the response of patients with proliferative LN who are treated following two prednisone therapy guidelines: reduced initial doses <30 mg/d and standard initial doses >30 mg/d during the induction stage. Method: clinical, analytical and therapeutic guidelines of patients with proliferative LN were compared and classified into two groups according to the standard or low-dose initial prednisone dose. Results: 21 patients with proliferative LN were studied (n=12 low-dose initial prednisonevs. n=9 standard initial prednisone). No significant differences were found between clinical and analytical variables, although a significantly different statistic difference was observed in the number of methylprednisone pulses (5 ± 2.95 initial prednisone <30 mg/d vs 2.33 ± 2.91 initial prednisone >30 mg/d, p = 0.041) and in the prednisone dose accumulated in 6 months (12.8 mg ± 4.9 initial prednisone <30 mg/d vs 30.0 ± 13.1 mg initial prednisone >30 mg/d, p =0.008). Rev Méd Urug 2021; 37(4): e37407